Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.

Messé SR, Fonarow GC, Smith EE, Kaltenbach L, Olson DM, Kasner SE, Schwamm LH.

Circ Cardiovasc Qual Outcomes. 2012 May;5(3):321-6. doi: 10.1161/CIRCOUTCOMES.111.964064. Epub 2012 May 1.

2.

Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.

Lin CB, Peterson ED, Smith EE, Saver JL, Liang L, Xian Y, Olson DM, Shah BR, Hernandez AF, Schwamm LH, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):514-22. doi: 10.1161/CIRCOUTCOMES.112.965210. Epub 2012 Jul 10.

3.

Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):543-9. doi: 10.1161/CIRCOUTCOMES.111.000303.

4.

Role of tissue plasminogen activator in acute ischemic stroke.

Hatcher MA, Starr JA.

Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Review.

PMID:
21386027
5.

Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.

Minnerup J, Wersching H, Ringelstein EB, Schilling M, Schäbitz WR, Wellmann J, Berger K.

Stroke. 2011 Oct;42(10):2838-43. doi: 10.1161/STROKEAHA.111.616565. Epub 2011 Aug 18.

6.

Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2014 Apr 23-30;311(16):1632-40. doi: 10.1001/jama.2014.3203.

PMID:
24756513
7.

Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.

Uchino K, Massaro L, Jovin TG, Hammer MD, Wechsler LR.

J Stroke Cerebrovasc Dis. 2010 Nov-Dec;19(6):417-23. doi: 10.1016/j.jstrokecerebrovasdis.2009.07.013. Epub 2010 Jun 17.

PMID:
21051004
8.

Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials.

Cronin CA.

J Emerg Med. 2010 Jan;38(1):99-105. doi: 10.1016/j.jemermed.2009.08.004. Epub 2009 Sep 17. Review.

PMID:
19765940
9.

Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window.

O'Brien EC, Rose KM, Patel MD, Murphy CV, Rosamond WD.

J Stroke Cerebrovasc Dis. 2012 Oct;21(7):541-6. doi: 10.1016/j.jstrokecerebrovasdis.2010.12.004. Epub 2011 Jan 14.

PMID:
21236701
10.

Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Epub 2012 Jun 19. Review.

PMID:
22708668
11.

Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?

Allen NB, Myers D, Watanabe E, Dostal J, Sama D, Goldstein LB, Lichtman JH.

Cerebrovasc Dis. 2009;27(3):254-8. doi: 10.1159/000196824. Epub 2009 Jan 29.

PMID:
19176959
12.

Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.

Shobha N, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study (CASES).

Cerebrovasc Dis. 2011;31(3):223-8. doi: 10.1159/000321893. Epub 2010 Dec 21.

PMID:
21178345
13.

Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.

Schwammenthal Y, Drescher MJ, Merzeliak O, Tsabari R, Bruk B, Feibel M, Hoffman C, Bakon M, Rotstein Z, Chapman J, Tanne D.

Isr Med Assoc J. 2004 Feb;6(2):70-4.

14.

Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.

Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

Circulation. 2011 Feb 22;123(7):750-8. doi: 10.1161/CIRCULATIONAHA.110.974675. Epub 2011 Feb 10.

15.

Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Lansberg MG, Bluhmki E, Thijs VN.

Stroke. 2009 Jul;40(7):2438-41. doi: 10.1161/STROKEAHA.109.552547. Epub 2009 May 28.

16.

Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.

Rost NS, Smith EE, Pervez MA, Mello P, Dreyer P, Schwamm LH.

Circ Cardiovasc Qual Outcomes. 2012 May;5(3):314-20. doi: 10.1161/CIRCOUTCOMES.111.962829. Epub 2012 Apr 24.

17.

Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier?

Laloux P, Thijs V, Peeters A, Desfontaines P.

Acta Neurol Belg. 2007 Dec;107(4):103-7.

PMID:
18416282
18.
19.

Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.

Wolfe T, Suarez JI, Tarr RW, Welter E, Landis D, Sunshine JL, Zaidat OO.

J Stroke Cerebrovasc Dis. 2008 May-Jun;17(3):121-8. doi: 10.1016/j.jstrokecerebrovasdis.2007.12.004.

PMID:
18436152
20.

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

de Los Ríos la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, Khatri P, Adeoye O, Woo D, Ferioli S, Kleindorfer DO.

Stroke. 2012 Jun;43(6):1591-5. doi: 10.1161/STROKEAHA.111.645986. Epub 2012 Mar 22.

Supplemental Content

Support Center